Voyager Therapeutics (NASDAQ: VYGR) reported Q1 EPS of ($0.20), $0.24 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $19.5 million versus the consensus estimate of $9.42 million.

Financial Guidance

Voyager is committed to maintaining a strong balance sheet that supports the advancement and growth of its platform and pipeline. Voyager continues to assess its planned cash needs both during the current period and in future periods. We expect our cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine and Novartis collaborations, certain near-term milestones, and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2027.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.